Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   ACTAVIS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-23
ACTAVIS
Dec-18
PANACEA BIOTECH/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs19116,159-   
Low Rs10710,840-   
Sales per share (Unadj.) Rs75.13,963.8-  
Earnings per share (Unadj.) Rs-5.5-1,276.8-  
Cash flow per share (Unadj.) Rs0.9417.7-  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs137.716,349.0-  
Shares outstanding (eoy) m61.25332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.03.4 58.4%   
Avg P/E ratio x-27.1-10.6 256.2%  
P/CF ratio (eoy) x170.032.3 526.0%  
Price / Book Value ratio x1.10.8 131.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m9,1424,489,898 0.2%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m1,2650-   
Avg. sales/employee Rs Th078,010.2-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,127.1-  
INCOME DATA
Net Sales Rs m4,5991,318,372 0.3%  
Other income Rs m51725,212 2.0%   
Total revenues Rs m5,1161,343,584 0.4%   
Gross profit Rs m4734,548 0.1%  
Depreciation Rs m391563,576 0.1%   
Interest Rs m4476,078 0.1%   
Profit before tax Rs m128-579,893 -0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,896 0.0%   
Tax Rs m466-7,349 -6.3%   
Profit after tax Rs m-337-424,648 0.1%  
Gross profit margin %1.02.6 39.0%  
Effective tax rate %363.51.3 28,685.8%   
Net profit margin %-7.3-32.2 22.8%  
BALANCE SHEET DATA
Current assets Rs m5,623540,727 1.0%   
Current liabilities Rs m3,297478,345 0.7%   
Net working cap to sales %50.64.7 1,068.7%  
Current ratio x1.71.1 150.9%  
Inventory Days Days5920 299.8%  
Debtors Days Days4866 71.9%  
Net fixed assets Rs m7,028149,232 4.7%   
Share capital Rs m610-   
"Free" reserves Rs m8,3750-   
Net worth Rs m8,4365,437,670 0.2%   
Long term debt Rs m2021,914,801 0.0%   
Total assets Rs m12,7128,500,316 0.1%  
Interest coverage x3.9-6.6 -58.7%   
Debt to equity ratio x00.4 6.8%  
Sales to assets ratio x0.40.2 233.3%   
Return on assets %-2.3-4.1 56.2%  
Return on equity %-4.0-7.8 51.2%  
Return on capital %2.0-4.8 -41.2%  
Exports to sales %43.30-   
Imports to sales %24.40-   
Net fx Rs m8010-   
CASH FLOW
From Operations Rs m-4,225471,005 -0.9%  
From Investments Rs m4,303258,756 1.7%  
From Financial Activity Rs m-184-808,385 0.0%  
Net Cashflow Rs m-105-78,232 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare PANACEA BIOTECH With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: SUDARSHAN PHARMA  PARMAX PHARMA  KERALA AYURV  SAROJA PHARMA INDUSTRIES INDIA LTD.  SEQUENT SCIENTIFIC  



Today's Market

Sensex Today Ends 456 Points Lower | IT Stocks Drag | 5 Reasons Why Indian Share Market is Falling Sensex Today Ends 456 Points Lower | IT Stocks Drag | 5 Reasons Why Indian Share Market is Falling(Closing)

After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.